Calcipotriene/Betamethasone Dipropionate Cream vs Calcipotriene/Betamethasone Dipropionate Foam
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: Vitamin D receptor + Glucocorticoid receptor · full Psoriasis pipeline
Calcipotriene/Betamethasone Dipropionate Cream · Wynzora
Marketed by MC2 Therapeutics
NCT03308799 · Phase 3 · completed
This randomized, investigator-blind Phase 3 trial gave calcipotriene/betamethasone dipropionate cream (MC2-01, Wynzora), CAL/BDP topical suspension or cream vehicle once daily for 8 weeks to 796 patients with psoriasis. The primary endpoint was PGA treatment success at week 8. The cream was significantly better than both the topical suspension (37.4% vs 22.8%) and the vehicle (3.7%), each P<0.0001, so the primary was met. Source: the peer-reviewed paper (Stein Gold et al., J Drugs Dermatol 2021), which cites this NCT number.
Reported efficacy
Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): MC2-01 Cream -67.5% (Standard Error 20.8) vs Cal/BDP Combination -63.5% (Standard Error 22.2) vs Vehicle -11.7% (Standard Error 21.9) (unclear)
Result source: NCT03802344
Calcipotriene/Betamethasone Dipropionate Foam · Enstilar
Marketed by LEO Pharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | Calcipotriene/Betamethasone Dipropionate Cream | Calcipotriene/Betamethasone Dipropionate Foam |
|---|---|---|
| PASI 75 | —Not reported | 50% vs 14.3%+35.7 vs placeboNCT034417892 other results
|
| PASI 90 | —Not reported | —Not posted · NCT03731091 |
| PASI 100 | —Not reported | —Not posted · NCT03731091 |
| sPGA 0/1 | —Not reported | —Not posted · NCT03731091 |
| DLQI, change | —Not reported | 3 vs 6−3 vs placeboNCT034417895 other results
|
PASI 75
- Calcipotriene/Betamethasone Dipropionate Cream
- —Not reported
- Calcipotriene/Betamethasone Dipropionate Foam
- 50% vs 14.3%+35.7 vs placeboNCT03441789
2 other results
- 28.6% vs 14.3% NCT03441789
- 50% vs 7.1% NCT03441789
PASI 90
- Calcipotriene/Betamethasone Dipropionate Cream
- —Not reported
- Calcipotriene/Betamethasone Dipropionate Foam
- —Not posted · NCT03731091
PASI 100
- Calcipotriene/Betamethasone Dipropionate Cream
- —Not reported
- Calcipotriene/Betamethasone Dipropionate Foam
- —Not posted · NCT03731091
sPGA 0/1
- Calcipotriene/Betamethasone Dipropionate Cream
- —Not reported
- Calcipotriene/Betamethasone Dipropionate Foam
- —Not posted · NCT03731091
DLQI, change
- Calcipotriene/Betamethasone Dipropionate Cream
- —Not reported
- Calcipotriene/Betamethasone Dipropionate Foam
- 3 vs 6−3 vs placeboNCT03441789
5 other results
- 5 vs 5 NCT03441789
- -6.4 vs -7.2 NCT03506477
- -6.5 vs -6.8 NCT03506477
- 2 vs 5 NCT03441789
- -4.4 vs -11.3 NCT03506477
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Calcipotriene/Betamethasone Dipropionate Cream: 3 of 4 rows · Calcipotriene/Betamethasone Dipropionate Foam: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Calcipotriene/Betamethasone Dipropionate Cream | Calcipotriene/Betamethasone Dipropionate Foam |
|---|---|---|
| Dropout rate | 8.3% NCT03308799 · Phase 3 · Psoriasis · phase 3 show 1 more result3.8% NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3 | 50%a NCT04227288 · Phase 4 · registry result, not featured evidence show 3 more results5% NCT03506477 · Phase 4 · registry result, not featured evidence 0% NCT03848871 · Phase 4 · registry result, not featured evidence 7.1% NCT03441789 · Phase 4 · registry result, not featured evidence · combination |
| Discontinued due to AEs | — NCT03308799 · Phase 3 · Psoriasis · phase 3 show 1 more result— NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3 | —a NCT04227288 · Phase 4 · registry result, not featured evidence show 3 more results— NCT03506477 · Phase 4 · registry result, not featured evidence — NCT03848871 · Phase 4 · registry result, not featured evidence 0% NCT03441789 · Phase 4 · registry result, not featured evidence · combination |
| Serious AEs | 3.3% NCT03308799 · Phase 3 · Psoriasis · phase 3 show 1 more result0.5% NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3 | 0%a NCT04227288 · Phase 4 · registry result, not featured evidence show 3 more results0% NCT03506477 · Phase 4 · registry result, not featured evidence 0% NCT03848871 · Phase 4 · registry result, not featured evidence 7.1% NCT03441789 · Phase 4 · registry result, not featured evidence · combination |
| Most frequent reported AEs | nasopharyngitis 4.7% (placebo 1.5%) NCT03802344 · Phase 3 · monotherapy · Psoriasis · phase 3 | a sinusitis 16.7% torn bicep 16.7% torn rotator cuff 16.7% NCT04227288 · Phase 4 · registry result, not featured evidence show 3 more resultscommon cold 15% (placebo 0%) diarrhea 10% (placebo 0%) upper extremity pain 10% (placebo 0%) NCT03506477 · Phase 4 · registry result, not featured evidence rhinorrhea 14.3% (placebo 0%) abdominal cramping 7.1% (placebo 0%) chest congestion 7.1% (placebo 0%) NCT03441789 · Phase 4 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Calcipotriene/Betamethasone Dipropionate Cream
show 1 more result
Calcipotriene/Betamethasone Dipropionate Foam
show 1 more result
show 1 more result
show 2 more results
show 1 more result
show 2 more results
show 1 more result
show 5 more results
show 1 more result
show 1 more result
show 2 more results
+ 1 further endpoint in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Calcipotriene/Betamethasone Dipropionate Cream's landscape · Calcipotriene/Betamethasone Dipropionate Foam's landscape